Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Zhejiang Cheng Yi Pharmaceutical Co PEG Ratio Related Terms
Zhejiang Cheng Yi Pharmaceutical Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Cheng Yi Pharmaceutical Co PEG Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Cheng Yi Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Cheng Yi Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Cheng Yi Pharmaceutical Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Zhejiang Cheng Yi Pharmaceutical Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) has a PEG Ratio of 2.58 as of Aug. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. This is 41% below median its historical median of 4.37. Over the past decade, Zhejiang Cheng Yi Pharmaceutical Co's PEG Ratio has ranged from 0.57 to 47.13. According to the industry distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #215 out of 349 companies in the Drug Manufacturers industry, placing it in the top 61.6%.
Is Zhejiang Cheng Yi Pharmaceutical Co's PEG Ratio too high?
Zhejiang Cheng Yi Pharmaceutical Co's current PEG Ratio of 2.58 is 41% below median its 10-year median of 4.37. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 47.13. The Drug Manufacturers industry median PEG Ratio is 1.80. Zhejiang Cheng Yi Pharmaceutical Co's value of 2.58 is 43.3% above this industry median. Based on the distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #215 out of 349 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhejiang Cheng Yi Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Cheng Yi Pharmaceutical Co's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #215 out of 349 companies for PEG Ratio. This places Zhejiang Cheng Yi Pharmaceutical Co in the lower half of its industry. The industry median PEG Ratio is 1.80. Zhejiang Cheng Yi Pharmaceutical Co's value of 2.58 is 43.3% above this benchmark. Historically, Zhejiang Cheng Yi Pharmaceutical Co's own PEG Ratio has ranged from 0.57 to 47.13 over the past decade. While the company's 10-year median is 4.37 vs. the industry median of 1.80, Zhejiang Cheng Yi Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.80, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Cheng Yi Pharmaceutical Co's current PEG Ratio of 2.58 is 43.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Cheng Yi Pharmaceutical Co's current PEG Ratio is 2.58, which is 41% below median its own 10-year median of 4.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Cheng Yi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥8.45, compared to a current price of ¥7.43 — trading 12.1% below its estimated fair value. The current PEG Ratio is 2.58, which is 41% below median its 10-year median of 4.37 and 43.3% above the Drug Manufacturers industry median of 1.80. Zhejiang Cheng Yi Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811), the current PEG Ratio is 2.58 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.43 is trading 12.1% below its estimated GF Value™ of ¥8.45.
GuruFocus considers Zhejiang Cheng Yi Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603811:
PEG Ratio: 2.58 (41% below median its 10-year median of 4.37)
GF Value™: ¥8.45 vs. price of ¥7.43 (12.1% below fair value)
Industry Position: 43.3% above the Drug Manufacturers median (#215 of 349)
No single metric tells the full story. See the SHSE:603811 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
85GF Score
Get the complete analysis for SHSE:603811
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603811 has been successfully added to your 
